Karyopharm Therapeutics (KPTI) Misses Q4 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Karyopharm Reports Fourth Quarter and Full Year 2014 Financial Results and Highlights Recent Progress
March 16, 2015 7:01 AM EDTInitiated Multiple Registration-directed Trials and Presented Positive Selinexor Clinical Data in 2014
Aggressive Selinexor Development Campaign Continues in 2015
Conference Call Scheduled for today at 8:30 a.m. ET
NEWTON, Mass., March 16, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today reported financial results for the fourth quarter and year ended December 31, 2014 and commented on recent accomplishments and clinical development plans for selinexor, its lead product candidate.
"We made significant progress advancing the development of our lead product candidate, selinexor, a... More
Karyopharm Reports Fourth Quarter and Full Year 2014 Financial Results and Highlights Recent Progress
March 16, 2015 7:01 AM EDTInitiated Multiple Registration-directed Trials and Presented Positive Selinexor Clinical Data in 2014
Aggressive Selinexor Development Campaign Continues in 2015
Conference Call Scheduled for today at 8:30 a.m. ET
NEWTON, Mass., March 16, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today reported financial results for the fourth quarter and year ended December 31, 2014 and commented on recent accomplishments and clinical development plans for selinexor, its lead product candidate.
"We made significant progress advancing the development of our lead product candidate, selinexor, a... More
